Share on LinkedInShare on LinkedIn

ARTICLE · 10 MARCH 2015

PTAB Sides With Petitioner In Pharmaceutical Inter Partes Reviews

The Patent Trial and Appeal Board ("PTAB") recently sided with petitioner BioMarin Pharmaceutical in three inter partes review proceedings involving Genzyme’s enzyme therapy product Myozyme®.

United StatesIntellectual Property

The Patent Trial and Appeal Board ("PTAB") recently sided with petitioner BioMarin Pharmaceutical in three inter partes review proceedings involving Genzyme's enzyme therapy product Myozyme®. The decisions mark one of the first times that the PTAB has invalidated a pharmaceutical patent in the context of an inter partes review. Cf., e.g., Gnosis Spa v. S. Ala. Med. Sci. Found., IPR2013-00116 (P.T.A.B. June 20, 2014).

Genzyme's Myozyme® is an injectable acid alpha glucosidase ("GAA") enzyme approved for treatment of Pompe disease. California-based biotechnology company BioMarin is developing a fusion-protein of insulin-like growth factor 2 and GAA for the treatment of the same condition.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from